[서울대학교] 의과대학 생화학교실 임용 공고

안녕하세요,

서울대학교 의과대학 생화학교실 주임교수 윤홍덕 입니다.

저희 교실은 서울대학교 의과대학의 연구를 선도하는 기초교실로서, 2022년 3월 임용예정의 법인교원 1인을 채용할 예정입니다.

https://medicine.snu.ac.kr/fnt/bbm/cla/selectClassInfoList.do?classTy=B#n

채용 분야는 최신기술 기반 의과학/생화학 분야입니다. 줄기세포, 유전자 편집, 대사 등 이외에도 다른 분야에 대하여도 열려 있습니다.

많은 분들이 우려하시는 내정자가 있다거나 특정 분야만 채용할 부분은 전혀 없습니다.

열린 분야로서 오직 지원자의 과거와 현재, 그리고 미래의 연구우수성에 의해서만 공정하게 평가될 것을 말씀드립니다.

학교에서의 정식 채용공고가 아래의 website에 공지되어 있습니다. 보다 구체적인 내용은 아래 website를 참조해 주십시오.

https://professor.snu.ac.kr/adm/public/hurt/rcrt/frame/index.jsp

서울의대 생화학교실에 교원으로 오시게 된다면 교실에서는 신임교원의 능력을 마음껏 펼칠 수 있도록 학교와 협력하여 인적/물적 자원의 지원을 아끼지 않을 것입니다.

연구자분들의 많은 지원을 기대합니다.

궁금하신 부분이 있으시면 저나 교실 의국장으로 계신 조성엽 교수에게 편하게 이메일 보내주시면 됩니다.

윤홍덕: hdyoun@snu.ac.kr

조성엽: csybio@snu.ac.kr

서울의대 생화학교실 주임교수 윤홍덕 배상

KWiSE Forum 4: September 30, 8:30 PM EST (October 1, 9:30 AM KST)

KWiSE (Korean-American Women in Science and Engineering)의 NIH지부 (회장, 김동연 박사)와 Washington DC 지부 (회장, Jinyoung Barnaby 박사) 에서 Korea Foundation의 후원으로 COVID-19을 주제로 온라인으로 한미 공동 포럼을 주최하고 있습니다. 이번 네번째 포럼은 한국시간으로10월 1일 오전 9시반부터 11시까지 진행될 예정입니다.  (미국동부시간 9월 30일 저녁 8:30-10시). 포럼의 주제는  “Monoclonal Antibodies as Therapeutics against SARS-CoV-2: From Development to Regulatory Approval” 입니다.

백신이 이미 개발되어 일반인에게 보급되고 있는 시점이지만 백신 접종후에도 시간이 경과하면서 점차 재감염의 가능성이 높아지는 지금의 상황을 고려할때 항체를 이용한 치료제 개발은 매우 시급하고 적절한 문제가 아닐 수 없습니다. 그러한 면에서 이번 포럼은 과학계를 포함하여 일반인에게도 어필하는 주제라고 생각합니다.

이번 포럼의 연사로는 셀트리온의 부사장님인 이수영 박사님과 미국 식품의약청 (FDA) 에서 team leader로 재직하시는 최수영 박사님 두분을 초청하였습니다. 이수영 박사님은 “Neutralizing Effect of CT-P59 Against SARS-CoV-2 Variants” 라는 주제로,  그리고 최수영 박사님은 “Monoclonal Antibodies Targeting SARS-CoV-2”라는 주제로 심도있고 유익한 강연을 해주실 예정입니다.

이번 포럼은 미국 FDA에 계시는 신양미 박사님이 좌장을 맡아 주시고, 미국 국립보건연구원(NIH) 에서 근무하시는 지영미 박사님의 사회로 진행될 예정입니다. 더 자세한 내용을 보시려면 첨부한 포럼 포스터와 프로그램을 참고하시기 바랍니다.

아래 링크를 통해 등록하시면 무료로 참여하실 수 있으니 많은 성원 부탁드립니다. 아울러 주위에 널리 알려주시면 대단히 감사하겠습니다.

등록링크: http:bit.ly/kwiseforum4

[US-Korea Conference] Innovation and Entrepreneurship Symposium (IES) & Startup Pitch Competition (Dec 15 – 18, 2021 @ Hyatt Regency Orange County, Garden Grove, CA)

KSEA(Korean-American Scientists and Engineers Association) is hosting its 3rd Innovation and Entrepreneurship Symposium (IES) during the US-Korea Conference on  December 15 – 18, 2021 at the Hyatt Regency Orange County, Garden  Grove, CA.  The symposium seeks to provide a cooperative environment for current and future aspiring entrepreneurs in the US and Korea to network with high-profile entrepreneurs and investors, listen to the stories of those who have successfully exited their companies, and learn about the best practices of startups, from protecting your intellectual property and assets to securing funding from venture capitalists and government agencies. The symposium program and additional information can be viewed on the UKC website and from the attached program overview.

For budding entrepreneurs, come pitch to potential investors at the Startup Pitch Competition about how your solution seeks to improve the synergy between the US and  Korea. We invite all entrepreneurial-minded American and Korean professionals to attend the IES during UKC 2021 and learn about growing cross-border business opportunities in the US and Korea today. About ten competition finalists will go head-to-head to compete for various awards, including cash awards. Additional details, including eligibility requirements and timeline, can be found here and from the attached program overview and the flyer.

Interested in competing? Apply at https://bit.ly/3jQzJ64 by Friday, October 1, 2021, 11:59 EDT. 

Questions? Send an email at spc.ksea@gmail.com.

We invite all entrepreneurial-minded professionals and students to attend the IES during UKC 2021 and learn about the continually growing cross-border partnership opportunities in the US and Korea. 

Thank you.

Byungkyu Brian Park, UKC 2021 Chair and KSEA President

Woo Il Lee, UKC 2021 Co-Chair and KOFST President

IES Organizing Committee Co-Chairs

Kyeong Ho Yang (Chair, KITEE) IL Minn (Co-Chair, Competition, Johns Hopkins University) Jeho Park (Co-Chair, Program, Claremont McKenna College) Kwangrog Kim (Co-Chair, Entrepreneurship, Primer Sazze Partners)

[삼양홀딩스 바이오팜 그룹] 의약바이오 연구소 수시채용 – 경기도 판교, Korea

삼양홀딩스 바이오팜 부문 의약바이오연구소는 신개념의 약물전달시스템(DDS, Drug Delivery System)연구와 생분해성 소재 기술을 보유한 연구기관입니다. 특히 본 연구소는 자체 DDS기술을 적용하여 기존 항암제의 부작용 감소 및 효능 증대로 개선된 항암제 개발에 성공하였고, 생분해성 기술이 적용된 생체분해성 수술용봉합사는 세계에서 3번째로 자체 개발에 성공한 의료기기로써 세계 45개국 150여 고객에게 수출하고 있습니다. 뿐만 아니라 최근에는 본격적인 Open innovation을 통한 합성신약개발 과제의 출범을 통해 글로벌경쟁력을 갖춘 R&D중심 제약회사로 거듭나고자 하는 노력을 경주하고 있습니다. 이에, 삼양홀딩스 바이오팜 부문 의약바이오연구소에서 함께 인류의 건강을 증진하고 삶의 질을 풍요롭게 하는 의약품 개발에 동참할 열정적이고 실행력을 겸비한 우수인재들을 아래와 같이 모시고자 합니다.

참고로, 화상 면접이 가능하므로 저희 사에 관심 있으신 분들의 CV를 우선적으로 저희가 확보(담당 : 김도현 사원, dohyun.kim1@samyang.co) 할 수 있다면 내부 논의를 거쳐 다음 단계 (면접 등)로의 진행이 가능하겠습니다.

■ 모집부문 (삼양홀딩스, 판교 의약바이오연구소)

[Teraimmune] Scientist I, R&D – Gaithersburg, MD

Job Description (TI-HR-013, v0.3 09-2021)
– Title: Scientist I
– Division: Research and Development
– Type of employment: full-time, annual employment renewal
– Available number of positions: 1
– Deadline for applications: 9/24/2020

The successful candidate will put their research efforts into discovering and developing immune cell-derived therapeutics for the treatment of B-cell lymphomas. S/he will participate as a team member driving research programs forward to the development and discovery of proof-of-concept studies for new pipelines of the business as well as research programs across different stages of pre-clinical live-cell therapeutics. The candidate must be motivated to design, execute, and interpret studies to develop new therapeutics and validate and characterize engineered immune cell therapeutic products but not limited. The fellow is encouraged to effectively and frequently collaborate with multidisciplinary teams.

About the Company:
TeraImmune, Inc. is a Maryland-based preclinical-stage biopharmaceutical company developing immune therapeutics using regulatory T cells (Tregs). By combining target-specific receptors with Tregs, the company provides CAR-Treg and TCR-Treg technologies to help patients with autoimmune diseases. In addition to Treg immunology, TeraImmune is expanding its range of scope in immune therapies to other immune cells and biologics as well as cancer therapeutics.
For more information, please see website: www.teraimmune.com.

Primary responsibilities (include, but are not limited to):
The successful candidate must lead a project as a scientist to develop anti-cancer cell therapy. Expertise in design, perform and interpret data in vitro and ex vivo experiments with experience in immunology, cancer biology, or cell biology is required. Proficiency in cell biology assays that may include flow cytometry, ELISA, cell proliferation, cellular cytotoxicity, immune cell isolation from whole blood or tissues, cell culture and transfection is expected but not necessary. Previous experience with T cell biology with a characterization of immune cell subsets is highly desirable. Analyzing and presenting data in peer-reviewed journals or conferences is required. Working independently to manage time and multiple experiments simultaneously is necessary for this position.
The candidate may have to contribute to various projects outside of his/her own and collaborate with stakeholders from all relevant functions and must demonstrate clear and professional verbal and written communication skills.

Basic Requirements
• Major in Cell Biology, Molecular Biology, Immunology, or related areas.

• Ph.D. degree or M.S. degree with 4+ years relevant laboratory experience (job
level to be adjusted based on amount of prior experience)
• Strong organizational and record-keeping skills required.

Benefits
The company offers medical and dental insurance. A 401(k) plan and student loan assistant program are optional. If required, the company is willing to petition VISA or green card application for the right candidate, but the applicant is responsible for his/her portions of processing and legal fee.

If you are interested in TeraImmune, please email a cover letter containing your interest experiences with a separate CV or resume as well as the contact information of at least two referees to HR manager at recruiting@teraimmune.com. Please feel free to email the HR manage with any questions and have a subject line of the email with the HR-number and the position title.

*TeraImmune, Inc. is an equal opportunity employer committed to employing a diverse workforce, including, but not limited to, minorities, females, individuals with disabilities, protected veterans, sexual orientation, gender identity Equal Employment Opportunity is The Law.